Capricor Reaffirms Confidence in Deramiocel Ahead of Nov. 22 FDA Decision

Capricor Therapeutics said on its third-quarter earnings call that it remains confident in deramiocel as the FDA’s November 22 target action date approaches. The application is in final review.